PureTech Health plc (LON:PRTC)
133.60
+0.20 (0.15%)
Apr 16, 2026, 8:51 AM GMT
PureTech Health Revenue
PureTech Health had revenue of $1.85M USD in the half year ending June 30, 2025, a decrease of -41.24%. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
$6.39M
Revenue Growth
+1,265.60%
P/S Ratio
69.61
Revenue / Employee
$114.13K
Employees
56
Market Cap
324.72M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
| Dec 31, 2017 | 2.54M | -1.90M | -42.79% |
| Dec 31, 2016 | 4.43M | -7.40M | -62.54% |
| Dec 31, 2015 | 11.83M | 9.61M | 432.31% |
| Dec 31, 2014 | 2.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Nanopore Technologies | 223.90M |
| Oxford Biomedica | 168.74M |
| hVIVO | 54.47M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
PureTech Health News
- 3 days ago - PureTech Health: Notice of Results - Business Wire
- 13 days ago - PureTech Health (PRTC) Advances Deupirfenidone for Pulmonary Fibrosis Treatment - GuruFocus
- 13 days ago - PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine - Business Wire
- 21 days ago - PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - Business Wire
- 7 weeks ago - PureTech to Present at the Leerink Partners Global Healthcare Conference - Business Wire
- 7 weeks ago - PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 3 months ago - PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire